News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bristol Myers Squibb (NYSE:BMY) is facing a revived US$6.7b lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb's drug, iberdomide (Zenbexus), has received accelerated FDA approval for treating multiple myeloma, making it the first FDA-approved cereblon-modulating (CELMoD) protein degrader. Zenbexus is indicated for use with Darzalex Faspro and dexamethasone in adults who have received at least one prior line …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …
Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …
Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval for ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy. This approval, based on …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%The U.S. FDA has approved Bristol Myers Squibb's combination treatment, iberdomide, for patients with a rare form of blood cancer called multiple myeloma. This treatment is intended for patients whose illness has relapsed or not responded to other therapies. Iberdomide works by targeting the …
Bristol Myers Squibb has chosen Houston, Texas, as the location for its new state-of-the-art manufacturing facility. This 60,000-square-foot site represents a $2.3 billion investment and is projected to create 500 skilled jobs in Generation Park. Construction is set to begin next year, with the …
A federal appeals court has reinstated a $6.7 billion lawsuit against Bristol Myers Squibb, brought by UMB Bank on behalf of former Celgene shareholders. The suit alleges Bristol Myers deliberately delayed FDA approvals for three drugs, including the cancer therapy Breyanzi, to avoid payouts …
Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and its acquisition MyoKardia. The suit aims to prevent a potential patent infringement case concerning Cytokinetics' heart disease treatment, Myqorzo (aficamten). The dispute involves U.S. Patent No. 12,616,697.
Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%AstraZeneca reportedly engaged in discussions with Bristol-Myers Squibb over the spring and summer regarding a potential acquisition. The talks were centered around AstraZeneca purchasing Bristol-Myers in a mostly stock-based deal at a premium.
Reports recently surfaced regarding a potential merger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb, causing significant industry speculation. Although a senior source reportedly debunked these rumors, the prospect of such a large-scale merger between two strong performers raised questions about its strategic rationale …
Bristol Myers Squibb announced plans for a $2.3 billion, 600,000-square-foot campus in Houston's Generation Park, expected to create nearly 500 skilled jobs by 2030. This investment is part of a larger $40 billion commitment to U.S. operations, aiming to boost domestic manufacturing and reduce …
Bristol Myers Squibb has announced a $2.3 billion investment to build a manufacturing campus in Houston, significantly increasing its initial estimate of $1 billion. The facility, expected to employ nearly 500 people and be completed by 2030, will produce small molecules, biologics, and antibody-drug …
Search by ticker symbol or company name and select a result to open its chart.